Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.52 |
| ▸ | PPARA | Q07869 | 2/20 | 0.52 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
| ▸ | PDE2A | O00408 | 3/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16333438 | 1.00 | PPARG (0.52) | PPARGPPARACTSSCTSKPDE2A | |
| SCHEMBL17776397 | 0.89 | PPARG (0.46) | PPARGPPARACTSSCTSKPDE2A | |
| SCHEMBL27159014 | 0.88 | CTSS (0.51) | PPARGPPARACTSSCTSKS1PR3 | |
| SCHEMBL12326946 | 0.88 | CTSS (0.51) | PPARGPPARACTSSCTSKS1PR3 | |
| SCHEMBL16633977 | 0.87 | PDE2A (0.51) | PPARGPPARACTSSCTSKPDE2A | |
| SCHEMBL266706 | 0.85 | CTSS (0.51) | PPARGPPARACTSSCTSKS1PR3 | |
| SCHEMBL1162807 | 0.85 | CTSS (0.51) | PPARGPPARACTSSCTSKS1PR3 | |
| SCHEMBL4815779 | 0.85 | CTSS (0.51) | PPARGPPARACTSSCTSKS1PR3 | |
| SCHEMBL20764658 | 0.85 | CTSS (0.49) | PPARGPPARACTSSCTSKCES2 | |
| SCHEMBL30117107 | 0.85 | CTSS (0.49) | PPARGPPARACTSSCTSKCES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3303367-B1 | STABILIZED MINIMAL COILED-COIL MIMETICS | UNIV NEW YORK (US) | 2025-06-18 | — | — | EP | disclosed |
| US-20240124539-A1 | CROSSLINKED HELIX DIMER MIMICS OF SOS AND METHODS OF USING SAME | NEW YORK UNIVERSITY | 2024-04-18 | — | — | US | disclosed |
| WO-2023078410-A1 | COMPOUND HAVING ACTIVITY OF DEGRADING GSPT1 AND APPLICATION THEREOF | 上海美志医药科技有限公司 | 2023-05-11 | — | — | WO | disclosed |
| US-11111214-B2 | Kappa opioid agonists and uses thereof | NEKTAR THERAPEUTICS (US) | 2021-09-07 | — | — | US | disclosed |
| US-20190352291-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS | 2019-11-21 | — | — | US | disclosed |
| EP-3013812-B1 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS (US) | 2019-10-16 | — | — | EP | disclosed |
| US-10017508-B2 | Nitrogenated heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-07-10 | — | — | US | disclosed |
| US-20170129887-A1 | NITROGENATED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-05-11 | — | — | US | disclosed |
| EP-2848618-A1 | NITROGENATED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-03-18 | — | — | EP | disclosed |
| EP-2350020-B1 | SPIRO-IMIDAZOLONE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-08-13 | — | — | EP | disclosed |
| US-20120232033-A1 | AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | KOLCZEWSKI SABINE (DE) | 2012-09-13 | — | — | US | disclosed |
| EP-2398558-A1 | AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2011-12-28 | — | — | EP | disclosed |
| WO-2011119559-A1 | NOVEL SPIRO IMIDAZOLONES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | SCHERING CORPORATION (US) | 2011-09-29 | — | — | WO | disclosed |
| US-7858639-B2 | [1,2,4]triazolo[4,3-a]pyridazine derivatives such as 6-(2-chlorophenyl)-7-(4-chlorophenyl)-3-[[2-methyl-6-(trifluoromethyl)pyridin-3-yl]methyl]-[1,2,4]triazolo[4,3-a]pyridine, used for the treatment of obesity and hyperlipemia, or as antidiabetic, antilipemic, anticholesterol and hypotensive agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-28 | — | — | US | disclosed |
| WO-2010094659-A1 | AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-26 | — | — | WO | disclosed |
| US-20100210592-A1 | AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | HOFFMANN-LA ROCHE, INC. | 2010-08-19 | — | — | US | disclosed |
| WO-2010039789-A1 | SPIRO-IMIDAZOLONE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2010-04-08 | — | — | WO | disclosed |
| US-20100048612-A1 | BICYCLIC HETEROCYCLES AS CANNABINOID-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-02-25 | — | — | US | disclosed |
| US-7632837-B2 | Bicyclic heterocycles as cannabinoid-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-15 | — | — | US | disclosed |
| US-20060287324-A1 | Bicyclic heterocycles as cannabinoid-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287324-A1 | Bicyclic heterocycles as cannabinoid-1 receptor modulators | CNR1, CNR2, GPR18 | PPARG 327/4885PPARA 639/4885CTSS 1988/4885 |
| US-20170129887-A1 | NITROGENATED HETEROCYCLIC COMPOUND | PDE2A, PDE5A, PDE3A | PPARG 1437/4885PPARA 1415/4885CTSS 3386/4885 |
| US-20190352291-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | OPRK1, OPRD1, OPRM1 | PPARG 220/4885PPARA 234/4885CTSS 2650/4885 |
| US-20240124539-A1 | CROSSLINKED HELIX DIMER MIMICS OF SOS AND METHODS OF USING SAME | SOS2, SOS1, F2 | PPARG 2882/4885PPARA 4384/4885CTSS 4337/4885 |
| US-11111214-B2 | Kappa opioid agonists and uses thereof | OPRK1, OPRD1, OPRM1 | PPARG 236/4885PPARA 249/4885CTSS 2692/4885 |
| US-20120232033-A1 | AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | GFPT1, CEPT1, SLC18A2 | PPARG 1522/4885PPARA 2580/4885CTSS 3935/4885 |
| US-10017508-B2 | Nitrogenated heterocyclic compound | PDE2A, PDE5A, PDE3A | PPARG 1437/4885PPARA 1415/4885CTSS 3386/4885 |
| US-20100210592-A1 | AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | GFPT1, CEPT1, SLC18A2 | PPARG 1522/4885PPARA 2580/4885CTSS 3935/4885 |
| US-20100048612-A1 | BICYCLIC HETEROCYCLES AS CANNABINOID-1 RECEPTOR MODULATORS | CNR1, CNR2, GPR18 | PPARG 327/4885PPARA 639/4885CTSS 1988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.